Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, Kakkar AK, Misselwitz F, Schellong S for the ODIXa-DVT Study Investigators
Treatment of proximal deep-vein thrombosis with the oral direct Factor Xa inhibitor rivaroxaban (BAY 59-7939). The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in patients with acute symptomatic Deep-Vein Thrombosis) Study
Circulation 2007;116(2):180–187

Bauer K, Homering M, Berkowitz S.
Effects of Age, Weight, Gender and Renal Function in a Pooled Analysis of Four Phase III Studies of Rivaroxaban for Prevention of Venous Thromboembolism after Major Orthopedic Surgery.
Blood (ASH Annual Meeting Abstracts) 2008;112:436

Büller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS, Misselwitz F, Raskob G, Schellong S, Segers A.
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor Rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis. The EINSTEIN-DVT Dose-Ranging Study.
Blood 2008;112:2242-2247

Eriksson B, Kakkar AK, Turpie AGG, Gent M, Bandel TJ, Homering M, Misselwitz F, Lassen MR
Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee arthroplasty
J Bone Joint Surg Br. 2009 May;91(5):636-44

Eriksson B, Turpie A, Lassen M, Kakkar A, Misselwitz F, Bandel TJ, Homering M, Westermeier T, Gent M.
A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effects of Specified Co-Medications.
Blood (ASH Annual Meeting Abstracts) 2008;112:1986

Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
N Engl J Med 2008;358:2765–2775

Gibson CM, Mega JL, Hammett CJ, Hricak V, Bordes P, Witkowski A,  Markov V, Burton P, Braunwald E.
Randomized Comparison of Rivaroxaban, an Oral Direct Factor Xa Inhibitor, with Placebo in Patients with Acute Coronary Syndromes: The ATLAS ACS-TIMI 46 Trial.
Circulation 2008;118:2311

Haas S.
Rivaroxaban - an oral, direct Factor Xa inhibitor - lessons from a broad clinical study programme
Eur J Haematol 2009 Jan 29;82(5):339-349

Halabi A, Kubitza D, Zuehlsdorf M, Becka M, Mueck W, Maatouk A
Effect of hepatic impairment on the pharmacokinetics, pharmacodynamics and tolerability of rivaroxaban – an oral, direct Factor Xa inhibitor.
J Thromb Haemost 2007;5(Suppl 2):Abstract P-M-635

Halabi A, Maatouk H, Klause N, Lufft V, Kubitza D, Zuehlsdorf M, Becka M, Mueck W, Schafers R, Wand D, Philipp T, Bruck H
Effects of renal impairment on the pharmacology of rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor.
Blood 2006;108:Abstract 913

Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap ÁF, Misselwitz, F, Haas S
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
Lancet 2008;372:31–39

Kwong L, Lees M, Sengupta N
Rivaroxaban for prevention of venous thromboembolism after total knee arthroplasty: impact on healthcare costs based on the RECORD3 study
Blood 2007;110(11):Abstract 1874

Lassen M.
Recent developments in the use of oral anticoagulants
Expert Opinion On Pharmacotherapy August 2009, Vol. 10, No. 11, Pages 1769-1781

Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AGG
Rivaroxaban for thromboprophylaxis after total knee arthroplasty
N Engl J Med 2008;358: 2776–2785

Mega J, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, Hricak V, Barnathan E, Bordes P, Witkowski A, Markov V, Oppenheimer L, Gibson C; on behalf of the ATLAS ACS-TIMI 46 study group.
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.
Lancet 2009 Jul 4;374(9683):29-38. Epub 2009 Jun 17.

Turpie A, Bauer K, Davidson B, Gent M, Kwong L, Lassen M, Cushner F, Lotke P, Berkowitz S, Bandel T-J, Misselwitz F, Fisher W.
Once-Daily Oral Rivaroxaban Compared with Subcutaneous Enoxaparin Every 12 Hours for Thromboprophylaxis after Total Knee Replacement: RECORD4.
Blood (ASH Annual Meeting Abstracts) 2008;112:35

Turpie A, Lassen M, Kakkar A, Eriksson B, Misselwitz F, Bandel TJ, Homering M, Westermeier T, Gent M.
A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effect on Symptomatic Venous Thromboembolism, Death, and Bleeding.
Blood (ASH Annual Meeting Abstracts) 2008;112:36

Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD; for the RECORD4 Investigators.
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Lancet 2009; 373(9676):1673-1680

Ageno W.
Rivaroxaban for the prevention of venous thromboembolism following major orthopedic surgery: the RECORD trials.
Expert Rev Cardiovasc Ther 2009;7:569-76

Bauer K, Homering M, Berkowitz S.
Effects of Age, Weight, Gender and Renal Function in a Pooled Analysis of Four Phase III Studies of Rivaroxaban for Prevention of Venous Thromboembolism after Major Orthopedic Surgery.
Blood (ASH Annual Meeting Abstracts) 2008;112:436

Borris LC.
New compounds in the management of venous thromboembolism after orthopedic surgery: focus on rivaroxaban
Vasc Health Risk Manag. 2008;4(4):855-62

Eriksson B, Kakkar AK, Turpie AGG, Gent M, Bandel TJ, Homering M, Misselwitz F, Lassen MR
Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee arthroplasty
J Bone Joint Surg Br. 2009 May;91(5):636-44

Eriksson B, Turpie A, Lassen M, Kakkar A, Misselwitz F, Bandel TJ, Homering M, Westermeier T, Gent M.
A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effects of Specified Co-Medications.
Blood (ASH Annual Meeting Abstracts) 2008;112:1986

Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
N Engl J Med 2008;358:2765–2775

Gruber A, Marzec U, Buetehorn U, Hanson S, Perzborn E.
Potential of Activated Prothrombin Complex Concentrate and Activated Factor VII to Reverse the Anticoagulant Effects of Rivaroxaban in Primates.
Blood (ASH Annual Meeting Abstracts) 2008;112:3825

Haas S.
Rivaroxaban - an oral, direct Factor Xa inhibitor - lessons from a broad clinical study programme
Eur J Haematol 2009 Jan 29;82(5):339-349

Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap ÁF, Misselwitz, F, Haas S
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
Lancet 2008;372:31–39

Kwong L, Lees M, Sengupta N
Rivaroxaban for prevention of venous thromboembolism after total knee arthroplasty: impact on healthcare costs based on the RECORD3 study
Blood 2007;110(11):Abstract 1874

Lassen M.
Recent developments in the use of oral anticoagulants
Expert Opinion On Pharmacotherapy August 2009, Vol. 10, No. 11, Pages 1769-1781

Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AGG
Rivaroxaban for thromboprophylaxis after total knee arthroplasty
N Engl J Med 2008;358: 2776–2785

Mega J, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, Hricak V, Barnathan E, Bordes P, Witkowski A, Markov V, Oppenheimer L, Gibson C; on behalf of the ATLAS ACS-TIMI 46 study group.
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.
Lancet 2009 Jul 4;374(9683):29-38. Epub 2009 Jun 17.

Turpie A, Bauer K, Davidson B, Gent M, Kwong L, Lassen M, Cushner F, Lotke P, Berkowitz S, Bandel T-J, Misselwitz F, Fisher W.
Once-Daily Oral Rivaroxaban Compared with Subcutaneous Enoxaparin Every 12 Hours for Thromboprophylaxis after Total Knee Replacement: RECORD4.
Blood (ASH Annual Meeting Abstracts) 2008;112:35

Turpie A, Lassen M, Kakkar A, Eriksson B, Misselwitz F, Bandel TJ, Homering M, Westermeier T, Gent M.
A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effect on Symptomatic Venous Thromboembolism, Death, and Bleeding.
Blood (ASH Annual Meeting Abstracts) 2008;112:36

Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD; for the RECORD4 Investigators.
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Lancet 2009; 373(9676):1673-1680

Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, Kakkar AK, Misselwitz F, Schellong S for the ODIXa-DVT Study Investigators
Treatment of proximal deep-vein thrombosis with the oral direct Factor Xa inhibitor rivaroxaban (BAY 59-7939). The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in patients with acute symptomatic Deep-Vein Thrombosis) Study
Circulation 2007;116(2):180–187

Bauer K, Homering M, Berkowitz S.
Effects of Age, Weight, Gender and Renal Function in a Pooled Analysis of Four Phase III Studies of Rivaroxaban for Prevention of Venous Thromboembolism after Major Orthopedic Surgery.
Blood (ASH Annual Meeting Abstracts) 2008;112:436

Büller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS, Misselwitz F, Raskob G, Schellong S, Segers A.
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor Rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis. The EINSTEIN-DVT Dose-Ranging Study.
Blood 2008;112:2242-2247

Eriksson B, Kakkar AK, Turpie AGG, Gent M, Bandel TJ, Homering M, Misselwitz F, Lassen MR
Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee arthroplasty
J Bone Joint Surg Br. 2009 May;91(5):636-44

Eriksson B, Turpie A, Lassen M, Kakkar A, Misselwitz F, Bandel TJ, Homering M, Westermeier T, Gent M.
A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effects of Specified Co-Medications.
Blood (ASH Annual Meeting Abstracts) 2008;112:1986

Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
N Engl J Med 2008;358:2765–2775

Haas S.
Rivaroxaban - an oral, direct Factor Xa inhibitor - lessons from a broad clinical study programme
Eur J Haematol 2009 Jan 29;82(5):339-349

Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap ÁF, Misselwitz, F, Haas S
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
Lancet 2008;372:31–39

Klein M, Perzborn E, Laux V, Schäfer S, von Degenfeld G.
The oral, direct factor Xa inhibitor rivaroxaban prevented right ventricular pressure increase and hypertrophy without increasing bleeding in a pulmonary artery hypertension model in rats.
Eur Heart J 2008;29(Abstract Supplement):564

Kubitza D, Becka M, Mueck W, Zuehlsdorf M
Rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor – has no clinically relevant interaction with naproxen
Br J Clin Pharmacol 2007;63:469–476

Kubitza D, Becka M, Mueck W, Zuehlsdorf M
Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban – an oral, direct Factor Xa inhibitor – are not affected by aspirin.
J Clin Pharmacol 2006;46:981–990

Kubitza D, Becka M, Mueck W, Zuehlsdorf M
Co-administration of rivaroxaban – a novel, oral, direct Factor Xa inhibitor – and clopidogrel in healthy subjects
Eur Heart J 2007;28(Suppl. 1):189

Kubitza D, Mueck W, Becka M
Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation.
Drug Saf 2008;31(1):67–77

Kwong L, Lees M, Sengupta N
Rivaroxaban for prevention of venous thromboembolism after total knee arthroplasty: impact on healthcare costs based on the RECORD3 study
Blood 2007;110(11):Abstract 1874

Lassen M.
Recent developments in the use of oral anticoagulants
Expert Opinion On Pharmacotherapy August 2009, Vol. 10, No. 11, Pages 1769-1781

Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AGG
Rivaroxaban for thromboprophylaxis after total knee arthroplasty
N Engl J Med 2008;358: 2776–2785

Mega J, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, Hricak V, Barnathan E, Bordes P, Witkowski A, Markov V, Oppenheimer L, Gibson C; on behalf of the ATLAS ACS-TIMI 46 study group.
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.
Lancet 2009 Jul 4;374(9683):29-38. Epub 2009 Jun 17.

Mueck W, Eriksson BI, Bauer KA, Borris L, Dahl OE, Fisher WD, Gent M, Haas S, Huisman MV, Kakkar AK, Kälebo P, Kwong LM, Misselwitz F, Turpie AGG
Population pharmacokinetics and pharmacodynamics of rivaroxaban – an oral, direct Factor Xa inhibitor – in patients undergoing major orthopaedic surgery
Clin Pharmacokinet 2008:47(3);203–216

Perzborn E, Buetehorn U, Fischer E, Harwardt M, Klages M, Trabandt A.
Hypercoagulability in rats is increased by low doses of the direct thrombin inhibitor melagatran , but is reduced by the direct factor Xa inhibitor rivaroxaban
Eur Heart J 2008;29(Abstract Supplement):825

Perzborn E, Harwardt M.
Direct Thrombin Inhibitors, but Not Factor Xa Inhibitors, Enhance Thrombin Formation in Human Plasma by Interfering with the Thrombin–Thrombomodulin–Protein C System.
Blood (ASH Annual Meeting Abstracts) 2008;112:528

ROCKET AF Executive Committee, Nessel C, Hacke W. Rivaroxaban
Once-daily, oral, direct Factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and Design of the ROCKET AF study
Ongoing Clinical Trials Posters 2009

Smith SA, Morrissey JH
Thromboplastin composition affects the sensitivity of prothrombin time (PT) clotting tests to direct Factor Xa inhibitors
Blood 2007;110(11):Abstract 928

Tinel H, Huetter J, Perzborn E
Partial reversal of the anticoagulant effect of high-dose rivaroxaban – an oral, direct Factor Xa inhibitor – by recombinant Factor VIIa in rats.
Blood 2006;108:Abstract 915

Turpie A, Bauer K, Davidson B, Gent M, Kwong L, Lassen M, Cushner F, Lotke P, Berkowitz S, Bandel T-J, Misselwitz F, Fisher W.
Once-Daily Oral Rivaroxaban Compared with Subcutaneous Enoxaparin Every 12 Hours for Thromboprophylaxis after Total Knee Replacement: RECORD4.
Blood (ASH Annual Meeting Abstracts) 2008;112:35

Turpie A, Lassen M, Kakkar A, Eriksson B, Misselwitz F, Bandel TJ, Homering M, Westermeier T, Gent M.
A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effect on Symptomatic Venous Thromboembolism, Death, and Bleeding.
Blood (ASH Annual Meeting Abstracts) 2008;112:36

Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD; for the RECORD4 Investigators.
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Lancet 2009; 373(9676):1673-1680

Turpie AGG
Warfarin replacements: mechanisms underlying emerging agents
Can J Cardiol 2008;24:56–60

Varin R, Mirshahi S, Mirshahi P, Lu-Hong L, Kierzek G, Vigneau JF, Marie J-P, Perzborn E, Mirshahi M, Soria C, Soria J.
Improvement of Thrombolysis by Rivaroxaban, an Anti Xa Inhibitor. Potential Therapeutic Importance in Patients with Thrombosis.
Blood (ASH Annual Meeting Abstracts) 2008;112:3031

Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, Kakkar AK, Misselwitz F, Schellong S for the ODIXa-DVT Study Investigators
Treatment of proximal deep-vein thrombosis with the oral direct Factor Xa inhibitor rivaroxaban (BAY 59-7939). The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in patients with acute symptomatic Deep-Vein Thrombosis) Study
Circulation 2007;116(2):180–187

Bauer K, Homering M, Berkowitz S.
Effects of Age, Weight, Gender and Renal Function in a Pooled Analysis of Four Phase III Studies of Rivaroxaban for Prevention of Venous Thromboembolism after Major Orthopedic Surgery.
Blood (ASH Annual Meeting Abstracts) 2008;112:436

Büller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS, Misselwitz F, Raskob G, Schellong S, Segers A.
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor Rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis. The EINSTEIN-DVT Dose-Ranging Study.
Blood 2008;112:2242-2247

Eriksson B, Kakkar AK, Turpie AGG, Gent M, Bandel TJ, Homering M, Misselwitz F, Lassen MR
Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee arthroplasty
J Bone Joint Surg Br. 2009 May;91(5):636-44

Eriksson B, Turpie A, Lassen M, Kakkar A, Misselwitz F, Bandel TJ, Homering M, Westermeier T, Gent M.
A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effects of Specified Co-Medications.
Blood (ASH Annual Meeting Abstracts) 2008;112:1986

Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
N Engl J Med 2008;358:2765–2775

Gruber A, Marzec U, Buetehorn U, Hanson S, Perzborn E.
Potential of Activated Prothrombin Complex Concentrate and Activated Factor VII to Reverse the Anticoagulant Effects of Rivaroxaban in Primates.
Blood (ASH Annual Meeting Abstracts) 2008;112:3825

Halabi A, Kubitza D, Zuehlsdorf M, Becka M, Mueck W, Maatouk A
Effect of hepatic impairment on the pharmacokinetics, pharmacodynamics and tolerability of rivaroxaban – an oral, direct Factor Xa inhibitor.
J Thromb Haemost 2007;5(Suppl 2):Abstract P-M-635

Halabi A, Maatouk H, Klause N, Lufft V, Kubitza D, Zuehlsdorf M, Becka M, Mueck W, Schafers R, Wand D, Philipp T, Bruck H
Effects of renal impairment on the pharmacology of rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor.
Blood 2006;108:Abstract 913

Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap ÁF, Misselwitz, F, Haas S
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
Lancet 2008;372:31–39

Kubitza D, Becka M, Mueck W, Zuehlsdorf M
Rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor – has no clinically relevant interaction with naproxen
Br J Clin Pharmacol 2007;63:469–476

Kubitza D, Mueck W, Becka M
Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation.
Drug Saf 2008;31(1):67–77

Kubitza D, Mueck W, Becka M
No interaction between rivaroxaban – a novel, oral, direct Factor Xa inhibitor- and atorvastatin.
Pathophysiol Haemost Thromb 2007/2008;36:A40

Kwong L, Lees M, Sengupta N
Rivaroxaban for prevention of venous thromboembolism after total knee arthroplasty: impact on healthcare costs based on the RECORD3 study
Blood 2007;110(11):Abstract 1874

Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AGG
Rivaroxaban for thromboprophylaxis after total knee arthroplasty
N Engl J Med 2008;358: 2776–2785

Mega J, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, Hricak V, Barnathan E, Bordes P, Witkowski A, Markov V, Oppenheimer L, Gibson C; on behalf of the ATLAS ACS-TIMI 46 study group.
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.
Lancet 2009 Jul 4;374(9683):29-38. Epub 2009 Jun 17.

Mueck W, Eriksson BI, Bauer KA, Borris L, Dahl OE, Fisher WD, Gent M, Haas S, Huisman MV, Kakkar AK, Kälebo P, Kwong LM, Misselwitz F, Turpie AGG
Population pharmacokinetics and pharmacodynamics of rivaroxaban – an oral, direct Factor Xa inhibitor – in patients undergoing major orthopaedic surgery
Clin Pharmacokinet 2008:47(3);203–216

Turpie A, Bauer K, Davidson B, Gent M, Kwong L, Lassen M, Cushner F, Lotke P, Berkowitz S, Bandel T-J, Misselwitz F, Fisher W.
Once-Daily Oral Rivaroxaban Compared with Subcutaneous Enoxaparin Every 12 Hours for Thromboprophylaxis after Total Knee Replacement: RECORD4.
Blood (ASH Annual Meeting Abstracts) 2008;112:35

Turpie A, Lassen M, Kakkar A, Eriksson B, Misselwitz F, Bandel TJ, Homering M, Westermeier T, Gent M.
A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effect on Symptomatic Venous Thromboembolism, Death, and Bleeding.
Blood (ASH Annual Meeting Abstracts) 2008;112:36

Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD; for the RECORD4 Investigators.
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Lancet 2009; 373(9676):1673-1680

Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, Kakkar AK, Misselwitz F, Schellong S for the ODIXa-DVT Study Investigators
Treatment of proximal deep-vein thrombosis with the oral direct Factor Xa inhibitor rivaroxaban (BAY 59-7939). The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in patients with acute symptomatic Deep-Vein Thrombosis) Study
Circulation 2007;116(2):180–187

Bauer K, Homering M, Berkowitz S.
Effects of Age, Weight, Gender and Renal Function in a Pooled Analysis of Four Phase III Studies of Rivaroxaban for Prevention of Venous Thromboembolism after Major Orthopedic Surgery.
Blood (ASH Annual Meeting Abstracts) 2008;112:436

Büller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS, Misselwitz F, Raskob G, Schellong S, Segers A.
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor Rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis. The EINSTEIN-DVT Dose-Ranging Study.
Blood 2008;112:2242-2247

Eriksson B, Kakkar AK, Turpie AGG, Gent M, Bandel TJ, Homering M, Misselwitz F, Lassen MR
Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee arthroplasty
J Bone Joint Surg Br. 2009 May;91(5):636-44

Eriksson B, Turpie A, Lassen M, Kakkar A, Misselwitz F, Bandel TJ, Homering M, Westermeier T, Gent M.
A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effects of Specified Co-Medications.
Blood (ASH Annual Meeting Abstracts) 2008;112:1986

Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
N Engl J Med 2008;358:2765–2775

Gibson CM, Mega JL, Hammett CJ, Hricak V, Bordes P, Witkowski A,  Markov V, Burton P, Braunwald E.
Randomized Comparison of Rivaroxaban, an Oral Direct Factor Xa Inhibitor, with Placebo in Patients with Acute Coronary Syndromes: The ATLAS ACS-TIMI 46 Trial.
Circulation 2008;118:2311

Haas S.
Rivaroxaban - an oral, direct Factor Xa inhibitor - lessons from a broad clinical study programme
Eur J Haematol 2009 Jan 29;82(5):339-349

Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap ÁF, Misselwitz, F, Haas S
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
Lancet 2008;372:31–39

Klein M, Perzborn E, Laux V, Schäfer S, von Degenfeld G.
The oral, direct factor Xa inhibitor rivaroxaban prevented right ventricular pressure increase and hypertrophy without increasing bleeding in a pulmonary artery hypertension model in rats.
Eur Heart J 2008;29(Abstract Supplement):564

Kubitza D, Becka M, Zuehlsdorf M, Mueck W
No interaction between the novel, oral direct Factor Xa inhibitor BAY 59-7939 and digoxin
J Clin Pharmacol 2006; 46(6):702

Kubitza D, Mueck W, Becka M
Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation.
Drug Saf 2008;31(1):67–77

Kubitza D, Mueck W, Becka M
No interaction between rivaroxaban – a novel, oral, direct Factor Xa inhibitor- and atorvastatin.
Pathophysiol Haemost Thromb 2007/2008;36:A40

Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AGG
Rivaroxaban for thromboprophylaxis after total knee arthroplasty
N Engl J Med 2008;358: 2776–2785

Mega J, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, Hricak V, Barnathan E, Bordes P, Witkowski A, Markov V, Oppenheimer L, Gibson C; on behalf of the ATLAS ACS-TIMI 46 study group.
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.
Lancet 2009 Jul 4;374(9683):29-38. Epub 2009 Jun 17.

Murray M, Wild D, Reaney M
Exploring patient satisfaction with long-term warfarin for the treatment of atrial fibrillation.
Blood 2005;106(11):Abstract 2245

Perzborn E, Fischer E, Lange U
Rivaroxaban, a novel, oral, direct Factor Xa inhibitor, enhanced the effects of clopidogrel and acetylsalicylic acid in rats
Eur Heart J 2007;28(Suppl. 1):189

ROCKET AF Executive Committee, Nessel C, Hacke W. Rivaroxaban
Once-daily, oral, direct Factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and Design of the ROCKET AF study
Ongoing Clinical Trials Posters 2009

Tinel H, Huetter J, Perzborn E
Partial reversal of the anticoagulant effect of high-dose rivaroxaban – an oral, direct Factor Xa inhibitor – by recombinant Factor VIIa in rats.
Blood 2006;108:Abstract 915

Turpie A, Bauer K, Davidson B, Gent M, Kwong L, Lassen M, Cushner F, Lotke P, Berkowitz S, Bandel T-J, Misselwitz F, Fisher W.
Once-Daily Oral Rivaroxaban Compared with Subcutaneous Enoxaparin Every 12 Hours for Thromboprophylaxis after Total Knee Replacement: RECORD4.
Blood (ASH Annual Meeting Abstracts) 2008;112:35

Turpie A, Lassen M, Kakkar A, Eriksson B, Misselwitz F, Bandel TJ, Homering M, Westermeier T, Gent M.
A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effect on Symptomatic Venous Thromboembolism, Death, and Bleeding.
Blood (ASH Annual Meeting Abstracts) 2008;112:36

Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD; for the RECORD4 Investigators.
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Lancet 2009; 373(9676):1673-1680

Turpie AGG
New oral anticoagulants in atrial fibrillation.
Eur Heart J 2008;29(2):155–165

Abdulsattar Y, Bhambri R, Nogid A.
Rivaroxaban (Xarelto) for the Prevention of Thromboembolic Disease: An Inside Look at the Oral Direct Factor Xa Inhibitor.
P T. 2009 May;34(5):238-244.

Abrams PJ, Emerson CR.
Rivaroxaban: a novel, oral, direct factor xa inhibitor.
Pharmacotherapy 2009 29:167-81

Ageno W.
Rivaroxaban for the prevention of venous thromboembolism following major orthopedic surgery: the RECORD trials.
Expert Rev Cardiovasc Ther 2009;7:569-76

Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, Kakkar AK, Misselwitz F, Schellong S for the ODIXa-DVT Study Investigators
Treatment of proximal deep-vein thrombosis with the oral direct Factor Xa inhibitor rivaroxaban (BAY 59-7939). The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in patients with acute symptomatic Deep-Vein Thrombosis) Study
Circulation 2007;116(2):180–187

Alacqua M, Mazzaglia G, Filippi A, Bianchi C, Shakespeare A, Cowell W, Cricelli C.
Persistence of oral anticoagulation therapy in atrial fibrillation: a retrospective cohort study in primary care in Italy.
Pharmacoepidemiol Drug Saf 2008;17:S61

Bauer K, Homering M, Berkowitz S.
Effects of Age, Weight, Gender and Renal Function in a Pooled Analysis of Four Phase III Studies of Rivaroxaban for Prevention of Venous Thromboembolism after Major Orthopedic Surgery.
Blood (ASH Annual Meeting Abstracts) 2008;112:436

Biemond BJ, Perzborn E, Friederich PW, Levi M, Buetehorn U, Büller HR
Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor
Thromb Haemost 2007;97:471–477

Borah B, McDonald H, Henk J, Crowther M, Selby R, Wells P.
Alignment to ACCP Prophylaxis Guidelines and VTE Outcomes in THR and TKR Patients.
Blood (ASH Annual Meeting Abstracts) 2008;112:170

Borchmann P, Eichhorst B, Hellmann M, Hübel K, Kochanek M, Kreuzer KA, Reiser M, Hallek M.
Hämatologie 2008
Dtsch Med Wochenschr 2008 Jun;133(25-26):1400-4.

Borris LC, Breindahl M, Lassen MR, Pap AF, Misselwitz F
Differences in Urinary Prothrombin Fragment 1+2 Levels After Total Hip Replacement in Relation to Venous Thromboembolism and Bleeding Events
J Thromb Haemos 2008 Aug 1 [Epub ahead of print]

Borris LC.
Barriers to the optimal use of anticoagulants after orthopaedic surgery.
Arch Orthop Trauma Surg 2008 Oct 8. [Epub ahead of print]

Borris LC.
New compounds in the management of venous thromboembolism after orthopedic surgery: focus on rivaroxaban
Vasc Health Risk Manag. 2008;4(4):855-62

Borris LC.
Rivaroxaban and dabigatran etexilate: two new oral anticoagulants for extended postoperative prevention of venous thromboembolism after elective total hip arthroplasty.
Arch Orthop Trauma Surg. 2009 Jun 30. [Epub ahead of print]

Büller HR, Agnelli G
Treatment of proximal deep vein thrombosis (DVT): Rivaroxaban once or twice daily had similar efficacy and safety to standard therapy in phase II studies
J Thromb Haemost 2007; 5 (Suppl 2):Abstract O-W-052

Büller HR, Agnelli G, Lensing AWA, Misselwitz F, the EINSTEIN-DVT and ODIXa-DVT Study groups
Rivaroxaban once or twice daily: similar efficacy and safety to standard therapy in dose-ranging studies for the treatment of proximal deep vein thrombosis
J Am Coll Cardiol 2007;49:364A

Büller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS, Misselwitz F, Raskob G, Schellong S, Segers A.
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor Rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis. The EINSTEIN-DVT Dose-Ranging Study.
Blood 2008;112:2242-2247

Chaplin S
Rivaroxaban: a new orally active direct inhibitor of Factor Xa
Future Prescriber 2008;9:11–19

Chen T, Lam S.
Rivaroxaban: an oral direct factor xa inhibitor for the prevention of thromboembolism.
Cardiol Rev 2009; 17(4):192-7

Dahl OE, Eriksson BI, Homering M, Bauer KA, Borris L, Fisher WD, Gent M, Haas S, Huisman MV, Kakkar AK, Kalebo P, Kwong LM, Misselwitz F, Turpie AGG.
The effect of patient age, gender and weight on the efficacy and safety of rivaroxaban (BAY 59-7939) for the prevention of venous thromboembolism after major orthopaedic surgery.
J Bone Joint Surg [Br] 2009;91-B(Suppl IV):76

Diamantopoulos A, Forster F, Brosa M, Lees M, Gilmour L, Ashley D, Piñol C.
Cost-effectiveness of rivaroxaban versus enoxaparin for thromboprophylaxis after total knee replacement in the UK and Spain.
Value Health 2008;11:A362-A659

Diamantopoulos A, Forster F, Brosa M, Lees M, Piñol C, Febrer L.
Cost-effectiveness of rivaroxaban versus enoxaparin for thromboprophylaxis after total hip replacement in Spain.
Value Health 2008;11:A362-A659

Diamantopoulos A, Forster F, Lees M, Gilmour L, Ashley D.
Cost-effectiveness of rivaroxaban versus enoxaparin for thromboprophylaxis after total hip replacement in the UK.
Value Health 2008;11:A362-A659

Diamantopoulos A, Forster F, Lees M, McDonald H.
Cost-effectiveness of rivaroxaban versus enoxaparin for thromboprophylaxis after total hip replacement in Canada.
Value Health 2008;11:A362-A659

Diamantopoulos A, LeReun C, Rasul F, Lees M, Kubin M, Wells P.
Indirect Comparisons of Rivaroxaban Versus Alternative Prophylaxes for the Prevention of VTE in Patients Undergoing Total Knee Replacement.
Blood (ASH Annual Meeting Abstracts) 2008;112:1292

Diamantopoulos A, LeReun C, Rasul F, Lees M, Kubin M.
Indirect comparisons of rivaroxaban vs alternative prophylaxes for the prevention of venous thromboembolism in patients undergoing total hip or total knee replacement.
Value Health 2008;11:A197

Drouet L.
Rivaroxaban: mode of action
Ann Fr Anesth Reanim 2008;27 Suppl 3:S9–S15

Eriksson B, Kakkar AK, Turpie AGG, Gent M, Bandel TJ, Homering M, Misselwitz F, Lassen MR
Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee arthroplasty
J Bone Joint Surg Br. 2009 May;91(5):636-44

Eriksson B, Turpie A, Lassen M, Kakkar A, Misselwitz F, Bandel TJ, Homering M, Westermeier T, Gent M.
A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effects of Specified Co-Medications.
Blood (ASH Annual Meeting Abstracts) 2008;112:1986

Eriksson BI, Borris L, Dahl OE, Haas S, Huisman MV, Kakkar AK, Misselwitz F, Kälebo P, for the ODIXa-HIP Study Investigators
Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement
J Thromb Haemost 2006;4:121–128

Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Misselwitz F, Muehlhofer E, Kälebo P
Dose-escalation study of rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor – for the prevention of venous thromboembolism in patients undergoing total hip replacement
Thromb Res 2007;120(5):685–693

Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Muehlhofer E, Dierig C, Misselwitz F, Kälebo P
A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939) for thromboprophylaxis after total hip replacement
Circulation 2006;114:2374–2381

Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
N Engl J Med 2008;358:2765–2775

Eriksson BI.
An introduction to rivaroxaban: the first oral, once-daily, direct Factor Xa inhibitor for the prevention of venous thromboembolism.
J Bone Joint Surg (Br) supplement Sept 2008:3–6.

Filippi A, Alacqua M, Shakespeare A, Mazzaglia G, Bianchi C, Cowell W, Cricelli C.
Management of atrial fibrillation with oral anticoagulants and predictors in clinical practice in Italy.
Eur Heart J 2008;29(Abstract Supplement):534

Fisher WD, Eriksson BI, Bauer KA, Borris L, Dahl OE, Gent M, Haas S, Homering M, Huisman MV, Kakkar AK, Kälebo P, Kwong LM, Misselwitz F, Turpie AG
Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies
Thromb Haemost 2007;97:931–937

Gerotziafas GT, Elalamy I, Perzborn E, Depasse F, Samama MM
In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct Factor Xa inhibitor rivaroxaban
J Thromb Haemost 2007;5:886–888

Gibson CM, Mega JL, Hammett CJ, Hricak V, Bordes P, Witkowski A,  Markov V, Burton P, Braunwald E.
Randomized Comparison of Rivaroxaban, an Oral Direct Factor Xa Inhibitor, with Placebo in Patients with Acute Coronary Syndromes: The ATLAS ACS-TIMI 46 Trial.
Circulation 2008;118:2311

Graff J, von Hentig N, Misselwitz F, Kubitza D, Becka M, Breddin HK, Harder S
Effects of the oral, direct Factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity
J Clin Pharmacol 2007;47:1398–1407

Gruber A, Marzec U, Buetehorn U, Hanson S, Perzborn E.
Potential of Activated Prothrombin Complex Concentrate and Activated Factor VII to Reverse the Anticoagulant Effects of Rivaroxaban in Primates.
Blood (ASH Annual Meeting Abstracts) 2008;112:3825

Gruber A, Marzec UM, Buetehorn U, Hanson SR, Perzborn E
Recombinant Factor VIIa reverses the effects of a high dose of rivaroxaban in baboons
Pathophysiol Haemost Thromb 2007/2008;36:A39

Gulseth MP, Michaud J, Nutescu EA
Rivaroxaban: an oral direct inhibitor of factor Xa
Am J Health Syst Pharm 2008;65:1520-9

Gurm HS, Eagle K.
Rivaroxaban in acute coronary syndromes: too soon to know?
Lancet 2009 Jul 4;374(9683):3-4. Epub 2009 Jun 17.

Haas S.
New anticoagulants - towards the development of an 'ideal' anticoagulant.
VASA 2009;38:13–29.

Haas S.
Rivaroxaban - an oral, direct Factor Xa inhibitor - lessons from a broad clinical study programme
Eur J Haematol 2009 Jan 29;82(5):339-349

Haertlein B, Parry TJ, Chen C, Perzborn E, Andrade-Gordon P, Damiano BP
Rivaroxaban An Oral, Direct Factor Xa Inhibitor Prevents Arterial Thrombotic Occlusion in Electrolytically Injured Rat Carotid Arteries
Blood 2007;110(11):Abstract: 3-a-4003

Halabi A, Kubitza D, Zuehlsdorf M, Becka M, Mueck W, Maatouk A
Effect of hepatic impairment on the pharmacokinetics, pharmacodynamics and tolerability of rivaroxaban – an oral, direct Factor Xa inhibitor.
J Thromb Haemost 2007;5(Suppl 2):Abstract P-M-635

Halabi A, Maatouk H, Klause N, Lufft V, Kubitza D, Zuehlsdorf M, Becka M, Mueck W, Schafers R, Wand D, Philipp T, Bruck H
Effects of renal impairment on the pharmacology of rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor.
Blood 2006;108:Abstract 913

Hoppensteadt D, Neville B, Cunanan J, Maddenini J, Perzborn E, Misselwitz F, Fareed J
Comparison of the anticoagulant properties of BAY 59-7939 – an oral, direct Factor Xa inhibitor – with fondaparinux and enoxaparin
J Thromb Haemost 2005;3(Suppl 1):Abstract P1120

Hoppensteadt D, Neville B, Schultz C, Cunanan J, Duff R, Perzborn E, Misselwitz F, Fareed J
Interaction of BAY 59-7939 – a novel, oral, direct Factor Xa inhibitor – with antiplatelet agents: monitoring and therapeutic applications
J Thromb Haemost 2005;3(Suppl 1):Abstract P1717

Kakar P, Watson T, Lip GY
Drug evaluation: Rivaroxaban, an oral, direct inhibitor of activated Factor X
Curr Opin Investig Drugs 2007;8:256–265

Kakar P, Watson T, Lip GY
Rivaroxaban.
Drugs Today 2007;43:129–136

Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap ÁF, Misselwitz, F, Haas S
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
Lancet 2008;372:31–39

Kakkar AK.
Rivaroxaban: venous thromboembolism risk reduction after total hip arthroplasty.
J Bone Joint Surg (Br) supplement Sept 2008:18–23.

Kamphuisen PW.
Thromboprophylaxis with rivaroxaban or enoxaparin did not differ for major bleeding in knee arthroplasty.
ACP J Club 2008;149:6-7.

Kamphuisen PW.
Thromboprophylaxis with rivaroxaban or enoxaparin did not differ for major bleeding or other safety outcomes in hip arthroplasty.
ACP J Club. 2008 Nov-Dec;149(4):6-7.

Klauser W.
What’s new in hip and knee surgery?
J Bone Joint Surg (Br) supplement Sept 2008:7–12.

Klein M, Perzborn E, Laux V, Schäfer S, von Degenfeld G.
The oral, direct factor Xa inhibitor rivaroxaban prevented right ventricular pressure increase and hypertrophy without increasing bleeding in a pulmonary artery hypertension model in rats.
Eur Heart J 2008;29(Abstract Supplement):564

Komotar RJ, Starke RM, Connolly ES Jr.
Orally administered factor xa inhibitor, rivaroxaban: a novel thromboembolic prophylaxis agent.
Neurosurgery 2008 Oct;63:N10-11

Kubitza D, Becka M, Mueck W, Zuehlsdorf
Pharmacology of the oral, direct Factor Xa inhibitor rivaroxaban – effect of extreme age and gender.
Hämostaseologie 2007;27:A40

Kubitza D, Becka M, Mueck W, Zuehlsdorf M
Aspirin Has No Effect on the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BAY 59–7939 – An Oral, Direct Factor Xa Inhibitor
J Thromb Haemost 2005; Volume 3, Supplement 1: P1105

Kubitza D, Becka M, Mueck W, Zuehlsdorf M
Rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor – has no clinically relevant interaction with naproxen
Br J Clin Pharmacol 2007;63:469–476

Kubitza D, Becka M, Mueck W, Zuehlsdorf M
Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban – an oral, direct Factor Xa inhibitor – are not affected by aspirin.
J Clin Pharmacol 2006;46:981–990

Kubitza D, Becka M, Mueck W, Zuehlsdorf M
The effect of extreme age, and gender, on the pharmacology and tolerability of rivaroxaban – an oral direct Factor Xa inhibitor.
Blood 2006;108:Abstract 905

Kubitza D, Becka M, Mueck W, Zuehlsdorf M
Co-administration of rivaroxaban – a novel, oral, direct Factor Xa inhibitor – and clopidogrel in healthy subjects
Eur Heart J 2007;28(Suppl. 1):189

Kubitza D, Becka M, Roth A, Mueck W.
Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects.
Curr Med Res Opin 2008;24:2757-2765.

Kubitza D, Becka M, Voith B, Zuehlsdorf M
Effect of enoxaparin on the safety, tolerability, pharmacodynamics, and pharmacokinetics of BAY 59-7939 – an oral, direct Factor Xa inhibitor
J Thromb Haemost 2005;3(Suppl 1):Abstract P1704

Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G
Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct Factor Xa inhibitor
Clin Pharmacol Ther 2005;78:412–421

Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M
Safety, pharmacodynamics and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects.
Eur J Clin Pharmacol2005;61:873–880

Kubitza D, Becka M, Zuehlsdorf M, Mueck W
Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects
J Clin Pharmacol 2006;46:549–558

Kubitza D, Becka M, Zuehlsdorf M, Mueck W
No interaction between the novel, oral direct Factor Xa inhibitor BAY 59-7939 and digoxin
J Clin Pharmacol 2006; 46(6):702

Kubitza D, Becka M, Zuehlsdorf M, Mueck W
Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects
J Clin Pharmacol 2007;47:218–226

Kubitza D, Haas S
Novel Factor Xa inhibitors for prevention and treatment of thromboembolic disease.
Expert Opin Investig Drugs 2006;15:843–855

Kubitza D, Mueck W, Becka M
Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation.
Drug Saf 2008;31(1):67–77

Kubitza D, Mueck W, Becka M
No interaction between rivaroxaban – a novel, oral, direct Factor Xa inhibitor- and atorvastatin.
Pathophysiol Haemost Thromb 2007/2008;36:A40

Kwong L, Diamantopoulos A, Forster F, Sengupta N, Lees M.
Will Rivaroxaban Be Cost-Effective for Prevention of Venous Thromboembolism after Total Hip Replacement in US Patients?
Blood (ASH Annual Meeting Abstracts) 2008;112:1290

Kwong L, Lees M, Sengupta N
Rivaroxaban for prevention of venous thromboembolism after total knee arthroplasty: impact on healthcare costs based on the RECORD3 study
Blood 2007;110(11):Abstract 1874

Kwong L, Sengupta N, Lees M.
Rivaroxaban for Prevention of Venous Thromboembolism after Total Knee Replacement: Impact on Healthcare Costs Based on the RECORD4 Study.
Blood (ASH Annual Meeting Abstracts) 2008;112:1289

Lang D, Freudenberger C, Weinz C.
In vitro metabolism of rivaroxaban – an oral, direct Factor Xa inhibitor – in liver microsomes and hepatocytes of rat, dog and man.
Drug Metab Dispos 2009;37(5):1046-55

Lassen M, Laux V.
Emergence of new oral antithrombotics: a critical appraisal of their clinical potential.
Vasc Health Risk Manag 2008:4;1373–1386

Lassen M.
Recent developments in the use of oral anticoagulants
Expert Opinion On Pharmacotherapy August 2009, Vol. 10, No. 11, Pages 1769-1781

Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AGG
Rivaroxaban for thromboprophylaxis after total knee arthroplasty
N Engl J Med 2008;358: 2776–2785

Lassen MR.
Rivaroxaban reduces symptomatic venous thromboembolism and has a potential positive economic impact after total knee arthroplasty.
J Bone Joint Surg (Br) supplement Sept 2008:24–29.

Laux V, Perzborn E, Kubitza D, Misselwitz F
Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct Factor Xa inhibitor.
Semin Thromb Haemost 2007;33(5):515–523

Lippi G, Franchini M, Targher G.
Rivaroxaban for thromboprophylaxis.
N Engl J Med 2008;359:2174; author Reply 2175-6

Lotke PA.
Rivaroxaban for thromboprophylaxis.
N Engl J Med 2008;359:2174; author reply 2175–6

Luiting W, Ros JJW.
Rivaroxaban (Xarelto).
Pharmaceutisch weekblad 2008;143:26–27.

Maclaine G, Wild D, Reaney M
Patient satisfaction with long-term warfarin for the treatment and secondary prevention of venous thromboembolism.
Pathophysiol Haemost Thromb 2006;35 (1–2):A44

Mantz J.
Rivaroxaban: a decisive step forward in the management of postoperative thromboembolic disease?
Ann Fr Anesth Reanim 2008;27 Suppl 3:S1

Mega J, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, Hricak V, Barnathan E, Bordes P, Witkowski A, Markov V, Oppenheimer L, Gibson C; on behalf of the ATLAS ACS-TIMI 46 study group.
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.
Lancet 2009 Jul 4;374(9683):29-38. Epub 2009 Jun 17.

Mismetti P, Laporte S.
Rivaroxaban: clinical pharmacology
Ann Fr Anesth Reanim 2008;27 Suppl 3:S16–S21.

Mueck W, Agnelli G, Büller H, (Intr by Misselwitz F)
Rivaroxaban has predictable pharmacokinetics (PK) and pharmacodynamics (PD) when given once or twice daily for the treatment of acute, proximal deep vein thrombosis (DVT)
Blood 2007;110(11):Abstract 1880

Mueck W, Becka M, Kubitza D, Voith B, Zuehlsdorf M
Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban – an oral, direct Factor Xa inhibitor – in healthy subjects
Int J Clin Pharm Ther 2007;45:335–344

Mueck W, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Kälebo P, Muelhofer E, Misselwitz F, Eriksson BI.
Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement.
Thromb Haemost 2008;100:453-61.

Mueck W, Eriksson BI, Bauer KA, Borris L, Dahl OE, Fisher WD, Gent M, Haas S, Huisman MV, Kakkar AK, Kälebo P, Kwong LM, Misselwitz F, Turpie AGG
Population pharmacokinetics and pharmacodynamics of rivaroxaban – an oral, direct Factor Xa inhibitor – in patients undergoing major orthopaedic surgery
Clin Pharmacokinet 2008:47(3);203–216

Mueck W, Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Kalebo P, Muehlhofer E, Misselwitz F
Rivaroxaban for thromboprophylaxis in patients undergoing total hip replacement: comparison of pharmacokinetics and pharmacodynamics with once- and twice-daily dosing
Blood 2006;108:Abstract 903

Murray M, Friedman H
A retrospective study of current anticoagulant use in patients with atrial fibrillation: results from a managed care database.
Blood 2005;106(11):Abstract 2246

Murray M, Wild D, Reaney M
Exploring patient satisfaction with long-term warfarin for the treatment of atrial fibrillation.
Blood 2005;106(11):Abstract 2245

Negrini C, Diamantopoulos A, Forster F, Lopatriello S, Lees M, Bianchi C, Pedone M.
Prophylaxis with rivaroxaban against venous thromboembolism (VTE): a cost-consequence analysis from the perspective of the Italian Healthcare Service.
Value Health 2008;11:A534

Paramanathan V.
Rivaroxaban: future in anticoagulation practice?
Hematology. 2008 Oct;13(5):257-60.

Perzborn E, Arndt B
Antithrombotic effects of concomitant administration of BAY 59-7939 with enoxaparin or heparin – interaction study
Blood 2004;104:Abstract 1863

Perzborn E, Arndt B, Fischer E, Harwardt M, Lange U, Trabandt A
Antithrombotic effects of rivaroxaban – an oral, direct Factor Xa inhibitor – in animal models of arterial and venous thrombosis: comparison with enoxaparin, an antithrombin-dependent anticoagulant
Eur Heart J 2006;27(Abstract Suppl):762

Perzborn E, Arndt B, Fischer E, Harwardt M, Lange U, Trabandt A.
Antithrombotic efficacy of rivaroxaban – an oral, direct Factor Xa inhibitor – and fondaparinux in animal models.
Pathophysiol Haemost Thromb 2006;35(1–2):A34.

Perzborn E, Arndt B, Fischer E, Harwardt M, Lange U, Trabant A
An in vivo risk–benefit comparison of the effects of rivaroxaban – an oral, direct Factor Xa inhibitor – with thrombin inhibitors, warfarin and clopidogrel.
J Thromb Haemost 2007;5(Suppl 2):Abstract P-W-638

Perzborn E, Arndt B, Harward M, Trabandt A
Antithrombotic efficacy of BAY 59-7939 – an oral, direct Factor Xa inhibitor – compared with fondaparinux in animal arterial thrombosis and thromboembolic death models
Eur Heart J 2005;26(Abstract Suppl):481

Perzborn E, Buetehorn U, Fischer E, Harwardt M, Klages M, Trabandt A.
Hypercoagulability in rats is increased by low doses of the direct thrombin inhibitor melagatran , but is reduced by the direct factor Xa inhibitor rivaroxaban
Eur Heart J 2008;29(Abstract Supplement):825

Perzborn E, Buetehorn U, Lampe T, Pernerstorfer J, Pohlmann J, Roehrig S, Schlemmer K-H, Straub A.
Antithrombotic effects of BAY 59-7939, an oral, direct Factor Xa inhibitor, in models of thrombosis and bleeding time in rats and rabbits
Pathophysiol Haemost Thromb 2004;33(Suppl. 2):Abstract PO053.

Perzborn E, Fischer E, Lange U
Rivaroxaban – a novel, oral, direct Factor Xa inhibitor – enhanced the antithrombotic effects of clopidogrel in rats
J Thromb Haemost 2007;5(Suppl 2):Abstract P-W-641

Perzborn E, Fischer E, Lange U
Rivaroxaban, a novel, oral, direct Factor Xa inhibitor, enhanced the effects of clopidogrel and acetylsalicylic acid in rats
Eur Heart J 2007;28(Suppl. 1):189

Perzborn E, Fischer E, Lange U
Combining rivaroxaban with acetylsalicylic acid increases antithrombotic potency without affecting bleeding times in animal models
J Thromb Haemost 2007;5(Suppl 2):Abstract P-W-639

Perzborn E, Harwardt M
Recombinant Factor VIIa partially reverses the effects of the Factor Xa inhibitor rivaroxaban on thrombin generation, but not the effects of thrombin inhibitors, in vitro
J Thromb Haemost 2007;5(Suppl 2):Abstract P-W-640

Perzborn E, Harwardt M.
Direct Thrombin Inhibitors, but Not Factor Xa Inhibitors, Enhance Thrombin Formation in Human Plasma by Interfering with the Thrombin–Thrombomodulin–Protein C System.
Blood (ASH Annual Meeting Abstracts) 2008;112:528

Perzborn E, Hirth-Dietrich C, Fischer E, Groth M, Hartmann E, Sperlich-Wulf K (Intr by Misselwitz F)
Rivaroxaban has protective effects in a model of disseminated intravascular coagulation (DIC) in rats
Blood 2007;110(11):Abstract 935

Perzborn E, Kubitza D, Misselwitz F
Rivaroxaban - A novel, oral, direct Factor Xa inhibitor in advanced clinical development for the prevention and treatment of thromboembolic disorders
Hämostaseologie 2007;27(4):282–289

Perzborn E, Lange U
Rivaroxaban – an oral, direct Factor Xa inhibitor – inhibits tissue factor-mediated platelet aggregation
J Thromb Haemost 2007;5(Suppl 2):Abstract P-W-642

Perzborn E, Strassburger J, Wilmen A, Lampe T, Pernerstorfer J, Pohlmann J, Roehrig S, Schlemmer K-H, Straub A.
Biochemical and pharmacologic properties of BAY 59-7939, an oral, direct Factor Xa inhibitor.
Pathophysiol Haemost Thromb 2004;33(Suppl. 2):Abstract PO079.

Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer KH, Straub A
In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 – an oral, direct Factor Xa inhibitor.
J Thromb Haemost 2005;3:514–521

Perzborn E, Tinel H
FEIBA reverses the effects of a high dose of rivaroxaban in rats
Pathophysiol Haemost Thromb 2007/2008;36:A40

Piccini JP, Patel MR, Mahaffey KW, Fox KA, Califf RM
Rivaroxaban, an oral direct Factor Xa inhibitor
Expert Opin Investig Drugs 2008;17:925–937

Pleiss U, Seidel D, Grosser R
Syntheses of [14C]BAY 59-7939 and its radiolabeled metabolite M-4
J Labelled Compd Rad 2006;49:929–934

ROCKET AF Executive Committee, Nessel C, Hacke W. Rivaroxaban
Once-daily, oral, direct Factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and Design of the ROCKET AF study
Ongoing Clinical Trials Posters 2009

Roehrig S, Straub A, Pohlmann J, Lampe T, Pernerstorfer J, Schlemmer K-H, Reinemer P, Perzborn E
Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide (BAY 59-7939): an oral, direct Factor Xa inhibitor
J Med Chem 2005;48:5900–5908

Rohde G
Determination of rivaroxaban - a novel, oral, direct Factor Xa inhibitor - in human plasma by high-performance liquid chromatography-tandem mass spectrometry
J Chromatogr B Analyt Technol Biomed Life Sci 2008 Jul 23 [Epub ahead of print]

Rosencher N, Arnaout L, Chabbouh T, Bellamy L.
Rivaroxaban (Xarelto): efficacy and safety
Ann Fr Anesth Reanim 2008;27 Suppl 3:S22–S27

Rosencher N, Bellamy N, Arnaout L.
Total hip and knee arthroplasty: an anaesthetist’s perspective.
J Bone Joint Surg (Br) supplement Sept 2008:13–17.

Samama M, Le Flem L, Guinet C, Perzborn E, Martinoli JL, Depasse F.
Effects of the Novel, Oral, Direct Factor Xa Inhibitor Rivaroxaban on Coagulation Assays.
Blood (ASH Annual Meeting Abstracts) 2008;112:3028

Samama MM, Le Flem L, Guinet C, Perzborn E, Depasse F
Measuring rivaroxaban pharmacodynamics: prothrombinase induced clotting time (PiCT®) and Heptest®
Pathophysiol Haemost Thromb 2008;36(suppl 1):A68 ABSTR P174

Samama MM, Le Flem L, Guinet C, Perzborn E, Martinoli JL, Depasse F
Effects of rivaroxaban and fondaparinux on clotting assays
Pathophysiol Haemost Thromb 2008;36(suppl 1):A68 ABSTR P173

Schellong SM, Beyer J, Kakkar AK, Halbritter K, Eriksson BI, Turpie Ag, Misselwitz F, Kalebo O
Ultrasound screening for asymptomatic deep vein thrombosis after major orthopaedic surgery: the VENUS study
J Thromb Haemost 2007;5(7):1431–1437

Schuman EP.
Rivaroxaban for thromboprophylaxis.
N Engl J Med 2008;359:2174; author reply 2175–6

Smith SA, Morrissey JH
Thromboplastin composition affects the sensitivity of prothrombin time (PT) clotting tests to direct Factor Xa inhibitors
Blood 2007;110(11):Abstract 928

Smith SA, Morrissey JH.
Polyphosphate as a general procoagulant agent.
J Thromb Haemost 2008;6:1750–1756

Steinle T, Ruppert A, Lees M.
Economic burden of venous thromboembolism in the general population and after major orthopedic surgery – results of a systematic literature review.
Value Health 2008;11:A201

Ten Cate H, Hamulyak K.
Rivaroxaban for thromboprophylaxis.
N Engl J Med 2008;359:2174–2175; author reply 2176

Tersteegen A, Burkhardt N
Rivaroxaban – an oral, direct Factor Xa inhibitor – binds rapidly to Factor Xa
J Thromb Haemost 2007;5(Suppl 2):Abstract P-W-651

Tinel H, Huetter J, Perzborn E
Recombinant Factor VIIa partially reverses the anticoagulant effect of high-dose rivaroxaban – a novel, oral, direct Factor Xa inhibitor – in rats
J Thromb Haemost 2007;5(Suppl 2):Abstract P-W-652

Tinel H, Huetter J, Perzborn E
Partial reversal of the anticoagulant effect of high-dose rivaroxaban – an oral, direct Factor Xa inhibitor – by recombinant Factor VIIa in rats.
Blood 2006;108:Abstract 915

Turpie A, Lassen M, Kakkar A, Eriksson B, Misselwitz F, Bandel TJ, Homering M, Westermeier T, Gent M.
A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effect on Symptomatic Venous Thromboembolism, Death, and Bleeding.
Blood (ASH Annual Meeting Abstracts) 2008;112:36

Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD; for the RECORD4 Investigators.
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Lancet 2009; 373(9676):1673-1680

Turpie AG. Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, Loscalzo J
Rivaroxaban in the Prevention and Treatment of Deep Venous Thrombosis (Update).
Harrison's Principles of Internal Medicine 17th Edition E-Published

Turpie AGG
New anticoagulant drugs in venous and arterial thrombosis
Haematologica Reports 2006; 2(4):10–11

Turpie AGG
New oral anticoagulants in atrial fibrillation.
Eur Heart J 2008;29(2):155–165

Turpie AGG
Warfarin replacements: mechanisms underlying emerging agents
Can J Cardiol 2008;24:56–60

Turpie AGG
Oral, direct Factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases.
Arterioscler Thromb Vasc Biol 2007;27(6):1238–1247

Turpie AGG, Eriksson BI, Mueck W, Bauer KA, Borris LC, Dahl OE, Fisher WD, Gent M, Haas S, Huisman MV, Kakkar AK, Kälebo P, Kwong LM, Misselwitz F
Pharmacokinetic and pharmacodynamic analyses of rivaroxaban in patients undergoing orthopaedic surgery
Pathophysiol Haemost Thromb 2006;35(1–2):A2

Turpie AGG, Fisher WD, Bauer KA, Kwong LM, Irwin MW, Kälebo P, Misselwitz F, Gent M, for the ODIXa-KNEE Study Group
BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study
J Thromb Haemost 2005;3:2479–2486

Turpie AGG, Lassen MR, Kakkar AK, Eriksson BI, Misselwitz F, Bandel TJ, Homering M, Westermeier T, Gent M
A meta-analysis of three pivotal studies of rivaroxaban – a novel, oral, direct Factor Xa inhibitor – for thromboprophylaxis after orthopaedic surgery
Pathophysiol Haemost Thromb 2008;36(suppl 1):A15 ABSTR O57

Turpie AGG.
Anticoagulants after orthopaedic surgery – where we are now?
J Bone Joint Surg (Br) Supplement Sept 2008:30–32.

Varin R, Mirshahi S, Mirshahi P, Lu-Hong L, Kierzek G, Vigneau JF, Marie J-P, Perzborn E, Mirshahi M, Soria C, Soria J.
Improvement of Thrombolysis by Rivaroxaban, an Anti Xa Inhibitor. Potential Therapeutic Importance in Patients with Thrombosis.
Blood (ASH Annual Meeting Abstracts) 2008;112:3031

Verma AK, Brighton TA
The direct factor Xa inhibitor rivaroxaban.
Med J Aust. 2009 Apr 6;190(7):379-83

Walenga JM, Hoppensteadt D, Iqbal O, Neville B, Jeske W, Prechel M, Messmore HL, Misselwitz F, Bakhos M
The oral, direct Factor Xa inhibitor BAY 59-7939 does not cross-react with anti-heparin/PF4 (heparin-induced thrombocytopenia) antibodies.
Blood 2005;106:Abstract 1883

Walenga JM, Prechel M, Jeske WP, Hoppensteadt D, Maddineni J, Iqbal O, Messmore HL, Bakhos M.
Rivaroxaban – an oral, direct Factor Xa inhibitor – has potential for the management of patients with heparin-induced thrombocytopenia
Br J Haem 2008;143:92-9.

Weinz C, Buetehorn U, Daehler H-P, Kohlsdorfer C, Pleiss U, Sandmann S, Schlemmer KH, Schwarz T, Steinke W
Pharmacokinetics of BAY 59-7939 – an oral, direct Factor Xa inhibitor – in rats and dogs
Xenobiotica 2005;35:891–910

Weinz C, Radtke M, Schmeer K, Kern A, Pleiss U
In vitro metabolism of BAY 59-7939 – an oral, direct Factor Xa inhibitor
Drug Metab Rev 2004;36(Suppl 1):Abstract 195

Weinz C, Schwarz T, Pleiss U, Shmeer K, Kubitza D, Mueck W, Gondol D, Aitken H
Metabolism and distribution of [14C]BAY 59-7939 – an oral, direct Factor Xa inhibitor – in rat, dog, and human
Drug Metab Rev 2004;36(Suppl 1):Abstract 196

Wells P, Diamantopoulos A, Forster F, Lees M, McDonald H.
Cost-Effectiveness of Rivaroxaban as VTE Prophylaxis after Total Hip Replacement in Canada.
Blood (ASH Annual Meeting Abstracts) 2008;112:1291

Wild D, Murray M, Shakespeare A, Reaney M, von Maltzahn R
Patient-reported treatment satisfaction measures for long-term anticoagulant therapy
Expert Review of Pharmacoeconomics & Outcomes Research 2008;8:291-299